• Release your full potential

    Be free to be active. Pioneering new territory to set new standards

ABOUT US

Pioneering novel treatment paradigms within immunology and inflammation (“I&I”). Read more about MC2 Therapeutics.

Platform

Our two first-in-class and novel mode of action drug candidates are “I&I pipeline in a drug” as they both have potential in multiple major underserved indications. We carefully select indications based on science, clinical unmet need and market access. Read more about our platform.

Pipeline

Based on our two first-in-class and novel mode of action drug candidates, we are currently pursuing indications where there are no or very limited approved treatment options. This includes MC2-32 a first-in-class oral HSP90 Inhibitor for Hidradenitis Suppurativa (Ph2a completed) and MC2-25 a topical first-in-class iso-cyanate scavenger for Vulvar Lichen Sclerosus (Ph2a ongoing). Read more about our pipeline.

LATEST NEWS

mc2_news-image-icon-05

MC2 Therapeutics Announces License, Supply and Commercialization Agreement for Wynzora® Cream in ASEAN Countries

Copenhagen, March 12th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing ...

READ FULL ARTICLE

mc2_news-image-icon-07

MC2 Therapeutics to Present at Upcoming Conferences

Copenhagen, February 26th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing ...

READ FULL ARTICLE

 

mc2_news-image-icon-07

MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial

  • MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the understanding and ...

    READ FULL ARTICLE

mc2_news-image-icon-05

MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

  • MC2-25 VLS is a first-in-class drug candidate for urea associated skin diseases using a di-peptide ...

    READ FULL ARTICLE